Norgalax (Docusate Sodium)

Docusate sodium reduces the surface tension of fecal material by acting as a surfactant. This allows water and fatty acids to penetrate the stool, increasing its water content and making it softer and easier to pass through the colon and rectum.

The specific dose of Norgalax is determined by the prescribing healthcare professional based on the patient’s condition, age, and response. The prescriber will select the appropriate amount and frequency of rectal administration according to clinical guidelines.

Safety data for docusate sodium in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details, and any necessary import documentation.

Norgalax (docusate sodium) is a surfactant laxative that softens stool by increasing water content, whereas osmotic laxatives such as lactulose draw water into the bowel by osmotic pressure. Docusate generally has a milder effect and is preferred for occasional constipation, while osmotic agents may be used for more severe cases.

Store Norgalax at room temperature, below 25 °C, in the original packaging. Keep the product away from excess moisture, direct sunlight, and heat sources to maintain its stability and effectiveness throughout its shelf life.

Norgalax is supplied as a rectal preparation, typically a suppository or enema. The product is inserted into the rectum according to the prescriber’s instructions, allowing the docusate sodium to act locally on the stool. Proper hygiene and positioning are important for optimal absorption.

Although rare, serious adverse reactions can include severe allergic responses such as rash, itching, swelling of the face or throat, and anaphylaxis. Rectal bleeding or persistent abdominal pain may also signal a more serious problem and should prompt immediate medical evaluation.

Norgalax should be avoided in individuals with known hypersensitivity to docusate sodium or any excipients, in patients with intestinal obstruction, perforated bowel, or acute abdominal conditions. It is also contraindicated for those with severe inflammatory bowel disease flare‑ups until the condition is stabilized.